All Posts Tagged With: "LGND"

(GSK) GlaxoSmithKline Drug Gets European Commission Approval

GlaxoSmithKline Plc. (GSK) recently received good news in the form of European approval for its oral thrombopoetin agonist, Revolade (eltrombopag). The European Commission (EC) granted marketing approval to...

16Mar2010 | | 0 comments | Continued

(GSK) GlaxoSmithKline Gains Positive European Medicines Agency Opinion

GlaxoSmithKline (GSK) recently received good news with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion for its oral thrombopoetin agonist,...

6Jan2010 | | 0 comments | Continued

(LGND) Ligand Pharmaceuticals to Buy Neurogen

Yesterday, Ligand Pharmaceuticals Inc. (LGND) announced it has agreed to purchase Neurogen (NRGN) for $11 million in stock as well as certain future cash payments based on licensing deals, real estate sales and other milestones.

The...

25Aug2009 | | 0 comments | Continued